The present application belongs to the field of
cell therapy and
immunotherapy, and provides a
genetically engineered human
trophoblast, a preparation method and application thereof. The human
trophoblast takes K562 cells as starting cells, and stably expresses membrane-bound
interleukin 21, CD137 ligand and
Delta-like ligand 1 after
genetic engineering. The constructed K562 three-factor
trophoblast can significantly improve the expansion efficiency, activation state and
functional stability of NK cells and γδT cells. The
synergistic mechanism includes enhancing the proliferation,
cytotoxicity and stemness maintenance of NK cells and γδT cells through STAT3, NF-κB and Notch signaling pathways, respectively. The human trophoblast has the advantages of good expression stability, significant functional enhancement, and
high activity after freezing and
recovery.